Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

Published:2013-08-22 Issue:2 Volume:16 Page:147-158
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kovacs C. S.¹,Seshiah V.²,Swallow R.³,Jones R.³,Rattunde H.⁴,Woerle H. J.⁴,Broedl U. C.⁴,

Affiliation:

1. Health Sciences Centre; Memorial University; Newfoundland Canada

2. Diabetes Care and Research Institute; Chennai India

3. Boehringer Ingelheim UK Ltd; Berkshire UK

4. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12188/fullpdf

Reference32 articles.

1. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia;DeFronzo;Diabetes Obes Metab,2012

2. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications;Gerich;Diabet Med,2010

3. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes;Rahmoune;Diabetes,2005

4. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012

5. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects;Seman;Clin Pharmacol Drug Dev,2013

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial;Diabetes & Metabolism Journal;2024-09-30

2. Diuretic Combination Therapy in Acute Heart Failure: An Updated Review;Current Pharmaceutical Design;2024-09

3. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study;Clinical Therapeutics;2024-09

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02);Journal of Diabetes Investigation;2024-05-04